SCHEMBL26655201

SCHEMBL26655201

Cc1ccc(S(=O)(=O)OCCCN2CCNCC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.53
ALDH1A1 P00352 3/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
MBTD1 Q05BQ5 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NMT1 P30419 1/20 0.44
CYP24A1 Q07973 1/20 0.43
HRH3 Q9Y5N1 3/20 0.42
HRH2 P25021 2/20 0.42
HRH1 P35367 2/20 0.42
HTR6 P50406 1/20 0.41
GAA P10253 1/20 0.41
TP53 P04637 1/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26655299 0.89 MEN1 (0.49) KDM4EALDH1A1NPC1RAB9AMBTD1
SCHEMBL2489147 0.86 L3MBTL1 (0.48) KDM4EALDH1A1NPC1RAB9AMBTD1
SCHEMBL2490457 0.86 L3MBTL1 (0.58) KDM4EALDH1A1RAB9AMBTD1L3MBTL1
Hydrochloric Acid SCHEMBL9449150 0.84 L3MBTL1 (0.57) KDM4EALDH1A1RAB9AMBTD1L3MBTL1
SCHEMBL2489249 0.83 HRH3 (0.56) KDM4EALDH1A1NPC1RAB9AHRH3
SCHEMBL28075446 0.82 HTR6 (0.44) KDM4EALDH1A1NPC1RAB9AHTR6
Tert-Butyl Formate SCHEMBL27942745 0.82 ALDH1A1 (0.42) KDM4EALDH1A1NPC1RAB9AMBTD1
SCHEMBL4541122 0.82 MEN1 (0.49) MBTD1L3MBTL1CYP24A1HRH3MEN1
SCHEMBL9162804 0.81 L3MBTL1 (0.56) KDM4EMBTD1L3MBTL1HRH3HRH1
SCHEMBL3975042 0.81 L3MBTL1 (0.49) ALDH1A1MBTD1L3MBTL1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001875-A1 AMINOPYRIMIDINYL DERIVATIVES FOR THE TREATMENT OF PARKINSON'S DISEASE UNIV DUNDEE (GB) 2026-01-01 US disclosed
EP-4522603-A1 AMINOPYRIMIDINYL DERIVATIVES FOR THE TREAMENT OF PARKINSON'S DISEASE University Of Dundee (GB) 2025-03-19 EP disclosed
WO-2023218187-A1 AMINOPYRIMIDINYL DERIVATIVES FOR THE TREAMENT OF PARKINSON'S DISEASE UNIVERSITY OF DUNDEE (GB) 2023-11-16 WO disclosed
EP-4276097-A1 AMINOPYRIMIDINYL DERIVATIVES FOR THE TREAMENT OF PARKINSON'S DISEASE University Of Dundee (GB) 2023-11-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001875-A1 AMINOPYRIMIDINYL DERIVATIVES FOR THE TREATMENT OF PARKINSON'S DISEASE LRRK2, XIAP, PARK7 KDM4E 1120/4885ALDH1A1 3061/4885NPC1 2775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.